Granulocytosis and thrombocytosis in renal cell carcinoma: a pro-inflammatory cytokine response originating in the tumour.
暂无分享,去创建一个
[1] M. Guida,et al. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors , 2007, Journal of Translational Medicine.
[2] M. Büchler,et al. Characterization of Primary Renal Carcinoma Cultures , 2007, Urologia Internationalis.
[3] C. Tzen,et al. Renal cell carcinoma producing granulocyte colony-stimulating factor. , 2006, Journal of the Formosan Medical Association = Taiwan yi zhi.
[4] A. Belldegrun,et al. Interleukin-6 and renal cell cancer: Production, regulation, and growth effects , 2005, Cancer Immunology, Immunotherapy.
[5] A. Meloni-Ehrig. Renal cancer: cytogenetic and molecular genetic aspects. , 2002, American journal of medical genetics.
[6] A. Ravaud,et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Razelle Kurzrock,et al. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. , 2002, Cancer research.
[8] G. Palapattu,et al. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. , 2002, Reviews in urology.
[9] U. Andersson,et al. Escherichia coli-induced expression of IL-1 alpha, IL-1 beta, IL-6 and IL-8 in normal human renal tubular epithelial cells. , 2001, Clinical and experimental immunology.
[10] J. McNeal,et al. Sarcomatoid Renal Cell Carcinoma of Papillary Origin , 2000 .
[11] A. Ermens,et al. Inverse relation between plasma G-CSF levels and neutrophil counts in a patient with autoimmune neutropenia treated with G-CSF. , 2000, Clinical and Laboratory Haematology.
[12] U. Junker,et al. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6? , 1999, Anticancer research.
[13] K. Grankvist,et al. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. , 1997, European journal of cancer.
[14] J. Blay,et al. Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma , 1997, International journal of cancer.
[15] L. Rink,et al. Cytokine production of neutrophils is limited to interleukin‐8 , 1996, Immunology.
[16] S. Kagawa,et al. A case of renal cell carcinoma producing granulocyte-macrophage colony-stimulating factor. , 1996, Journal of Urology.
[17] É. Lepage,et al. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. , 1994, European journal of cancer.
[18] H. Imura,et al. Thrombocytosis in patients with tumors producing colony-stimulating factor. , 1992, Blood.
[19] T. Hirano,et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. , 1991, Journal of the National Cancer Institute.